CD19-HLE-BiTE

N/A

Report date: 2026/03/19 17:01:25

Base Information

Drug NameCD19-HLE-BiTE

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionImmunostimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-CD3

TargetsT cell surface glycoprotein CD3

Therapy Area/IndicationsHematologic NeoplasmsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAmgen Chemical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesAmgen Chemical Co Ltd

Inactive CompaniesN/A

Active IndicationsHematologic NeoplasmsMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A